aumolertinib

Aumolertinib (also known as almonertinib) is an orally bioavailable, third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Developed by Hansoh Pharmaceutical, it is specifically designed to target both EGFR-sensitizing mutations (such as Exon 19 deletion and L858R) and the T790M resistance mutation while sparing wild-type EGFR. This selectivity profile is intended to reduce off-target toxicities, such as skin rash and diarrhea, which are common with earlier-generation TKIs. Aumolertinib was first approved in China for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) who have progressed on or after prior EGFR TKI therapy, and it has since received approval for the first-line treatment of patients with locally advanced or metastatic EGFR-mutated NSCLC. It is frequently evaluated in real-world clinical settings and in combination with other modalities, including radiotherapy and chemotherapy.

Brand names

Ameile

Other names

almonertinibaminostatinibaminostatineibHS10296HS-10296HS 10296